Use of ultra-high performance liquid chromatography-high-resolution mass spectroscopy to profile the metabolites from the serum of patients with breast cancer

Zhang,Qinqin; Lu,Rongzhao; Wu,Ying; Hong,Yong; Wang,Ningxia; Wang,Cunchuan

doi:10.3892/ol.2024.14342

Use of ultra-high performance liquid chromatography-high-resolution mass spectroscopy to profile the metabolites from the serum of patients with breast cancer

Authors:
- Qinqin Zhang
- Rongzhao Lu
- Ying Wu
- Yong Hong
- Ningxia Wang
- Cunchuan Wang
View Affiliations

Affiliations: Department of Breast Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China, School of Clinical Medicine, Guilin Medical University, Guilin, Guangxi Zhuang Autonomous Region 541001, P.R. China, Department of Thyroid and Breast Surgery, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, Guangxi Zhuang Autonomous Region 541002, P.R. China, Department of Gastrointestinal Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong 510630, P.R. China
Published online on: March 14, 2024 https://doi.org/10.3892/ol.2024.14342
Article Number: 209
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer (BC) is the most common type of malignancy and the leading cause of cancer‑associated mortality in women worldwide. As such, assessing the metabolic changes during human breast carcinogenesis is key for developing disease prevention methods and treatment. In the present study, non‑targeted metabolomics with chemometrics based on ultra‑high performance liquid chromatography‑high‑resolution mass spectrometry were performed to assess differences in serum metabolite patterns between patients with BC and healthy individuals. A total of 3,246 metabolites in the sera of healthy controls and patients with BC were found. Kyoto Encyclopedia of Genes and Genomes pathway analysis demonstrated that arginine, proline, nicotinate, nicotinamide, caffeine and arachidonic acid metabolism, as well as fatty acid biosynthesis were significantly altered in patients with BC in comparison with controls. These results suggested that serum metabolic profiling has potential for discovering molecular biomarkers for the detection of BC. It may also further the understanding of the underlying mechanisms associated with this disease.

View Figures

View References

1	Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, Vignat J, Gralow JR, Cardoso F, Siesling S and Soerjomataram I: Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast. 66:15–23. 2022. View Article : Google Scholar : PubMed/NCBI
2	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
3	Fakhri N, Chad MA, Lahkim M, Houari A, Dehbi H, Belmouden A and El Kadmiri N: Risk factors for breast cancer in women: An update review. Med Oncol. 39:1972022. View Article : Google Scholar : PubMed/NCBI
4	Derakhshan F and Reis-Filho JS: Pathogenesis of triple-negative breast cancer. Annu Rev Pathol. 17:181–204. 2022. View Article : Google Scholar : PubMed/NCBI
5	Wong GL, Manore SG, Doheny DL and Lo HW: STAT family of transcription factors in breast cancer: Pathogenesis and therapeutic opportunities and challenges. Semin Cancer Biol. 86:84–106. 2022. View Article : Google Scholar : PubMed/NCBI
6	Warburg O, Wind F and Negelein E: The metabolism of tumors in the body. J Gen Physiol. 8:519–530. 1927. View Article : Google Scholar : PubMed/NCBI
7	Li S, Zeng H, Fan J, Wang F, Xu C, Li Y, Tu J, Nephew KP and Long X: Glutamine metabolism in breast cancer and possible therapeutic targets. Biochem Pharmacol. 210:1154642023. View Article : Google Scholar : PubMed/NCBI
8	Hamam R, Hamam D, Alsaleh KA, Kassem M, Zaher W, Alfayez M, Aldahmash A and Alajez NM: Circulating microRNAs in breast cancer: Novel diagnostic and prognostic biomarkers. Cell Death Dis. 8:e30452017. View Article : Google Scholar : PubMed/NCBI
9	Gyamfi J, Kim J and Choi J: Cancer as a metabolic disorder. Int J Mol Sci. 23:11552022. View Article : Google Scholar : PubMed/NCBI
10	Ling ZN, Jiang YF, Ru JN, Lu JH, Ding B and Wu J: Amino acid metabolism in health and disease. Signal Transduct Target Ther. 8:3452023. View Article : Google Scholar : PubMed/NCBI
11	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
12	Guan Q, Liang S, Wang Z, Yang Y and Wang S: ¹H NMR-based metabonomic analysis of the effect of optimized rhubarb aglycone on the plasma and urine metabolic fingerprints of focal cerebral ischemia-reperfusion rats. J Ethnopharmacol. 154:65–75. 2014. View Article : Google Scholar : PubMed/NCBI
13	Dudzik D, Barbas-Bernardos C, García A and Barbas C: Quality assurance procedures for mass spectrometry untargeted metabolomics. a review. J Pharm Biomed Anal. 147:149–173. 2018. View Article : Google Scholar : PubMed/NCBI
14	Huang S, Chong N, Lewis NE, Jia W, Xie G and Garmire LX: Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis. Genome Med. 8:342016. View Article : Google Scholar : PubMed/NCBI
15	Ogrodzinski MP, Teoh ST and Lunt SY: Metabolomic profiling of mouse mammary tumor-derived cell lines reveals targeted therapy options for cancer subtypes. Cell Oncol (Dordr). 43:1117–1127. 2020. View Article : Google Scholar : PubMed/NCBI
16	Araújo R, Bispo D, Helguero LA and Gil AM: Metabolomic studies of breast cancer in murine models: A review. Biochim Biophys Acta Mol Basis Dis. 1866:1657132020. View Article : Google Scholar : PubMed/NCBI
17	Sharma U and Jagannathan NR: Magnetic resonance imaging (MRI) and MR spectroscopic methods in understanding breast cancer biology and metabolism. Metabolites. 12:2952022. View Article : Google Scholar : PubMed/NCBI
18	Choi MH: Mass spectrometry-based metabolic signatures of sex steroids in breast cancer. Mol Cell Endocrinol. 466:81–85. 2018. View Article : Google Scholar : PubMed/NCBI
19	Huan T, Forsberg EM, Rinehart D, Johnson CH, Ivanisevic J, Benton HP, Fang M, Aisporna A, Hilmers B, Poole FL, et al: Systems biology guided by XCMS Online metabolomics. Nat Methods. 14:461–462. 2017. View Article : Google Scholar : PubMed/NCBI
20	Yuan M, Breitkopf SB, Yang X and Asara JM: A positive/negative ion-switching, targeted mass spectrometry-based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue. Nat Protoc. 7:872–881. 2012. View Article : Google Scholar : PubMed/NCBI
21	Griffin JL and Shockcor JP: Metabolic profiles of cancer cells. Nat Rev Cancer. 4:551–561. 2004. View Article : Google Scholar : PubMed/NCBI
22	Kim YS, Maruvada P and Milner JA: Metabolomics in biomarker discovery: Future uses for cancer prevention. Future Oncol. 4:93–102. 2008. View Article : Google Scholar : PubMed/NCBI
23	Spratlin JL, Serkova NJ and Eckhardt SG: Clinical applications of metabolomics in oncology: A review. Clin Cancer Res. 15:431–440. 2009. View Article : Google Scholar : PubMed/NCBI
24	Mishra P and Ambs S: Metabolic signatures of human breast cancer. Mol Cell Oncol. 3:e9922172015. View Article : Google Scholar : PubMed/NCBI
25	Johnson CH, Manna SK, Krausz KW, Bonzo JA, Divelbiss RD, Hollingshead MG and Gonzalez FJ: Global metabolomics reveals urinary biomarkers of breast cancer in a mcf-7 ×enograft mouse model. Metabolites. 3:658–672. 2013. View Article : Google Scholar : PubMed/NCBI
26	Johnson CH, Patterson AD, Idle JR and Gonzalez FJ: Xenobiotic metabolomics: Major impact on the metabolome. Annu Rev Pharmacol Toxicol. 52:37–56. 2012. View Article : Google Scholar : PubMed/NCBI
27	Szefel J, Danielak A and Kruszewski WJ: Metabolic pathways of L-arginine and therapeutic consequences in tumors. Adv Med Sci. 64:104–110. 2019. View Article : Google Scholar : PubMed/NCBI
28	Hu L, Gao Y, Cao Y, Zhang Y, Xu M, Wang Y, Jing Y, Guo S, Jing F, Hu X and Zhu Z: Identification of arginine and its ‘Downstream’ molecules as potential markers of breast cancer. IUBMB Life. 68:817–822. 2016. View Article : Google Scholar : PubMed/NCBI
29	Kim S, Lee M, Song Y, Lee SY, Choi I, Park IS, Kim J, Kim JS, Kim KM and Seo HR: Argininosuccinate synthase 1 suppresses tumor progression through activation of PERK/eIF2α/ATF4/CHOP axis in hepatocellular carcinoma. J Exp Clin Cancer Res. 40:1272021. View Article : Google Scholar : PubMed/NCBI
30	Qiu F, Chen YR, Liu X, Chu CY, Shen LJ, Xu J, Gaur S, Forman HJ, Zhang H, Zheng S, et al: Arginine starvation impairs mitochondrial respiratory function in ASS1-deficient breast cancer cells. Sci Signal. 7:ra312014. View Article : Google Scholar : PubMed/NCBI
31	Park KG, Heys SD, Harris CI, Steele RJ, McNurlan MA, Eremin O and Garlick PJ: Arginine metabolism in benign and malignant disease of breast and colon: Evidence for possible inhibition of tumor-infiltrating macrophages. Nutrition. 7:185–188. 1991.PubMed/NCBI
32	Vissers YL, Dejong CH, Luiking YC, Fearon KC, von Meyenfeldt MF and Deutz NE: Plasma arginine concentrations are reduced in cancer patients: Evidence for arginine deficiency? Am J Clin Nutr. 81:1142–1146. 2005. View Article : Google Scholar : PubMed/NCBI
33	Geng D, Sun D, Zhang L and Zhang W: The therapy of gefitinib towards breast cancer partially through reversing breast cancer biomarker arginine. Afr Health Sci. 15:594–597. 2015. View Article : Google Scholar : PubMed/NCBI
34	Navas LE and Carnero A: Nicotinamide adenine dinucleotide (NAD) metabolism as a relevant target in cancer. Cells. 11:26272022. View Article : Google Scholar : PubMed/NCBI
35	Yin J, Ren W, Huang X, Deng J, Li T and Yin Y: Potential mechanisms connecting purine metabolism and cancer therapy. Front Immunol. 9:16972018. View Article : Google Scholar : PubMed/NCBI
36	Ortea I, González-Fernández MJ, Ramos-Bueno RP and Guil-Guerrero JL: Proteomics study reveals that docosahexaenoic and arachidonic acids exert different in vitro anticancer activities in colorectal cancer cells. J Agric Food Chem. 66:6003–6012. 2018. View Article : Google Scholar : PubMed/NCBI
37	Chan TA, Morin PJ, Vogelstein B and Kinzler KW: Mechanisms underlying nonsteroidal antiinflammatory drug-mediatedapoptosis. Proc Natl Acad Sci USA. 95:681–686. 1998. View Article : Google Scholar : PubMed/NCBI
38	Li W, Guo X, Chen C and Li J: The prognostic value of arachidonic acid metabolism in breast cancer by integrated bioinformatics. Lipids Health Dis. 21:1032022. View Article : Google Scholar : PubMed/NCBI